EMA Issues Brexit Guidance
The agency released guidance for industry regarding the United Kingdom’s withdrawal from the European Union.
On May 31, 2017, the European Medicines Agency (EMA) and the European Commission published guidance on how pharmaceutical companies can prepare for Brexit. The guidance offers information on centralized procedures and other agency activities. The guidance is one in a series of guidance documents the agency plans to publish on the effects of the United Kingdom’s withdrawal from the European Union.
Specifically, the guidance answers some of the industry’s questions regarding the implication of Brexit on marketing authorizations, orphan drug designations, and pharmacovigilance. The document address concerns regarding the location of personnel, documents, and manufacturing facilities currently located in the UK.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
